Olav Bergheim, Chairman
Olav Bergheim has over 30 years of experience in creating and managing life science companies. He is a founder of Kato Pharmaceuticals, Inc., in addition to several other successful life science companies including Volcano Corporation, 3F Therapeutics (acquired by Medtronic), Glaukos Corporation, Lonestar Heart Inc., Prelude Corporation and Metronom Health, Inc. Mr. Bergheim is also the founder of Fjord Ventures LLC, a life science accelerator located in Laguna Hills, California, where Kato was created. Mr. Bergheim was the chairman of Vessix Vascular, Inc. (acquired by Boston Scientific). Prior to starting Fjord Ventures, he spent 10 years at Domain Associates as a company creator and general partner. Prior to Domain, Mr. Bergheim spent 18 years with Baxter Healthcare at US and international locations, where he held various leadership and operating roles. Mr. Bergheim was a Corporate VP of Baxter as well as President of Baxter Germany, President of Baxter’s Cardiovascular Group (now Edwards Life Sciences) and General Manager of the Nordic area.
Terrance McGovern, Chief Executive Officer
Mr. McGovern is a co-founder of Kato. He also founded Volante Diagnostics, a developer of biomarkers for brain pathologies. He is the co-developer of the Kato extended release technology, which delivers Resolvine to the retinal surface and is the named inventor on several patents. Prior to Kato he was Managing Partner of Numoda Capital, an early stage investor in biotechnology companies. He also founded Crystal Cove Capital, a NASD Broker Dealer which provided investment banking services to public and private emerging healthcare companies. He has held CEO and CFO positions in numerous early stage companies. Earlier in his career he held senior management positions at Duff and Phelps, CIBC and Burns Fry Ltd. now a subsidiary of Bank of Montreal. He holds a BS in Biology from Georgetown University, an MS in Mammalian Physiology from Rutgers University, and an MBA from the Wharton School of business at the University of Pennsylvania.
Charles W.G. Eifrig, Chief Medical Officer
Charles Eifrig, M.D., F.A.C.S. received his Doctor of Medicine degree at the University of North Carolina School of Medicine. Dr. Eifrig finished his residency at Bascom Palmer Eye Institute in Miami, Florida where he completed a vitreoretinal medical and surgical fellowship. Dr. Eifrig also served as the “Team Eye Surgeon” for the Carolina Hurricanes of the National Hockey League (NHL) from 2005-2008. He has authored numerous papers in the peer-reviewed ophthalmology literature and participated in various clinical trials.
Hugh Neuharth, Chief Financial Officer
Mr. Neuharth has over 20 years experience with life sciences companies in senior operating, finance, and corporate M&A roles in start-ups and multinational enterprises. Mr. Neuharth has served as CFO to Cianna Medical, Inc, Glaukos Corporation and BioLucent, Inc. Prior to Kato, Mr. Neuharth worked with Smith & Nephew plc, a FTSE-100 life sciences company, for 11 years, most recently as Director, Corporate Change Programs and Finance (US equivalent – Senior VP/Regional COO and CFO/Regional Board Director) of Smith & Nephew’s Australasia Region based in Melbourne, Australia. Mr. Neuharth began his career with Ernst & Whinney in 1985.
Eric Chun, Director of Clinical Affairs
With 30 years experience in the pharmaceutical industry, 20+ years in clinical development, and 15 years experience in ophthalmology clinical drug development, Mr. Chun has worked in both drug and device research, and on both the Sponsor side as well as the CRO side of the industry. He has functioned as a Global Project Team Leader for multiple highly visible clinical programs in his previous positions at Allergan and as a Clinical Operations Director at Valeant Pharmaceuticals and at Biosense Webster (within the Johnson & Johnson Medical Devices division). In his current position, Mr. Chun will oversee the upcoming Clinical Phase 2 studies in diabetic retinopathy for Kato Pharmaceuticals.
Jeda Voska, Sr. Mgr. Research & Development
Degree in Chemistry from UCSB and a Masters in Chemical Engineering from USC. Expertise with material science engineering, biomaterials, analytical chemistry and wet chemistry techniques. Ms. Voska has supported medical device and pharmaceutical innovation, formulation, GMP manufacturing and commercialization of products.